TRCT
LTRN icon

Tower Research Capital (TRC)’s Lantern Pharma LTRN Stock Holding History

Tower Research Capital (TRC)’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85K Sell
1,162
-2,407
-67% -$7.06K ﹤0.01% 4336
2026
Q1 		$4.89K Buy
3,569
+2,728
+324% +$7.63K ﹤0.01% 4160
2025
Q4 		$2.55K Buy
841
+411
+96% +$1.53K ﹤0.01% 4504
2025
Q3 		$1.87K Sell
430
-727
-63% -$3.03K ﹤0.01% 4719
2025
Q2 		$3.66K Buy
1,157
+365
+46% +$1.23K ﹤0.01% 4454
2025
Q1 		$2.8K Sell
792
-471
-37% -$1.95K ﹤0.01% 4504
2024
Q4 		$4.03K Sell
1,263
-252
-17% -$863 ﹤0.01% 4536
2024
Q3 		$5.56K Buy
1,515
+176
+13% +$725 ﹤0.01% 4251
2024
Q2 		$6.25K Sell
1,339
-2,017
-60% -$12.1K ﹤0.01% 4600
2024
Q1 		$29.5K Buy
3,356
+2,192
+188% +$11.7K ﹤0.01% 2665
2023
Q4 		$4.98K Sell
1,164
-693
-37% -$2.44K ﹤0.01% 4891
2023
Q3 		$6.33K Sell
1,857
-482
-21% -$2.19K ﹤0.01% 4612
2023
Q2 		$13.2K Buy
2,339
+222
+10% +$1.15K ﹤0.01% 3797
2023
Q1 		$10K Buy
2,117
+2,089
+7,461% +$11K ﹤0.01% 4367
2022
Q4 		$0 Sell
28
-3,789
-99% -$19K ﹤0.01% 6177
2022
Q3 		$19K Buy
3,817
+2,690
+239% +$14.5K ﹤0.01% 3976
2022
Q2 		$6K Buy
1,127
+354
+46% +$2.11K ﹤0.01% 4935
2022
Q1 		$6K Sell
773
-839
-52% -$5.6K ﹤0.01% 4898
2021
Q4 		$13K Buy
1,612
+1,082
+204% +$9.88K ﹤0.01% 4187
2021
Q3 		$6K Buy
530
+178
+51% +$2.3K ﹤0.01% 4762
2021
Q2 		$5K Buy
352
+290
+468% +$4.48K ﹤0.01% 4726
2021
Q1 		$1K Sell
62
-531
-90% -$9.31K ﹤0.01% 5191
2020
Q4 		$11K Sell
593
-116
-16% -$2K ﹤0.01% 4249
2020
Q3 		$13K Buy
709
+539
+317% +$7.8K ﹤0.01% 3993
2020
Q2 		$2K Buy
+170
New +$2.2K ﹤0.01% 4513

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Tower Research Capital (TRC)'s LTRN Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Lantern Pharma (LTRN) stake by 67% in Q2 2026, selling an estimated $7.06K and leaving 1,162 shares worth $4.85K. The position accounts for ﹤0.01% of the portfolio, ranked #4336.

Tower Research Capital (TRC) first reported a position in LTRN in Q2 2020 and has held it in 25 quarters since. The position peaked at $29.5K in Q1 2024. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Tower Research Capital (TRC) held 1,162 shares of Lantern Pharma worth $4.85K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,407 Lantern Pharma shares in Q2 2026, an estimated $7.06K.
  • Lantern Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4336 holding.
  • Tower Research Capital (TRC) first reported a position in Lantern Pharma in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Lantern Pharma position peaked at $29.5K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.